Targeting immune checkpoint regulators such as PD-1 and PD-L1 with monoclonal antibodies has revolutionised the treatment of a number of cancers (Topalian et al. 2012; Brahmer et al. 2012; Robert et al. 2015). The gene discussed is PDCD1; the disease is cancer.